Data gathered: January 21
AI Stock Analysis - Novo Nordisk (NVO)
Analysis generated January 17, 2025. Powered by Chat GPT.
Novo Nordisk is a globally recognized pharmaceutical company specializing in the treatment of diabetes, obesity, and other chronic diseases. The company, headquartered in Denmark, has a long-standing history of innovation and serves patients in over 170 countries. With a mission to drive change to defeat diabetes and other serious chronic diseases, Novo Nordisk is deeply committed to research and development, accounting for a significant portion of its annual budget.
Stock Alerts - Novo Nordisk (NVO)
 |
Novo Nordisk | January 18 Reddit mentions are up by 317% in the last 24h. |
|
Novo Nordisk | January 17 Price is down by -5.1% in the last 24h. |
|
Novo Nordisk | January 15 Reddit mentions are up by 258% in the last 24h. |
|
Novo Nordisk | January 14 Price is down by -5.1% in the last 24h. |
Alternative Data for Novo Nordisk
About Novo Nordisk
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents.
| Price | $78.69 |
| Target Price | Sign up |
| Volume | 20,700,000 |
| Market Cap | $353B |
| Year Range | $78.69 - $146.35 |
| Dividend Yield | 1.84% |
| PE Ratio | 26.86 |
| Analyst Rating | 57% buy |
| Earnings Date | February 5 '25 |
| Industry | Drug Manufacturers |
In the news
Novo Nordisk A/S - share repurchase programmeJanuary 20 - GlobeNewswire |
|
 |
Novo Nordisk dethroned as Europe's biggest company by market capitalizationJanuary 20 - Biztoc.com |
 |
LVMH dethrones Novo Nordisk as Europe’s most valuable company as Bernard Arnault adds $12 billion to net worth in 2025January 20 - Biztoc.com |
Jim Cramer’s Comments on Novo Nordisk A/S (NVO) Surrounded Its Weight Loss Drugs Being Picked For Medicare Price NegotiationsJanuary 19 - Yahoo Entertainment |
|
 |
Novo Nordisk A/S (NYSE:NVO) Stock Price Down 4.6% – What’s Next?January 19 - ETF Daily News |
|
Hennion & Walsh Asset Management Inc. Buys 1,701 Shares of Novo Nordisk A/S (NYSE:NVO)January 19 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 71.3B | 11.3B | 60B | 27.3B | 37.4B | 0.900 |
| Q2 '24 | 68.1B | 10.3B | 57.8B | 20.1B | 35.7B | 0.660 |
| Q1 '24 | 65.3B | 9.92B | 55.4B | 25.4B | 35.3B | 0.830 |
| Q4 '23 | 65.9B | 10B | 55.8B | 22B | 30.6B | 0.710 |
| Q3 '23 | 58.7B | 9.71B | 49B | 22.5B | 29.4B | 0.730 |
Insider Transactions View All
No recorded Insider transactions.
Similar companies
| Company | Price | AI Score | |
|---|---|---|---|
 |
Johnson & JohnsonJNJ |
$147.03 0% | 46 |
 |
Eli Lilly and CompanyLLY |
$725.72 0% | 66 |
 |
PfizerPFE |
$26.3 0% | 38 |
 |
AstrazenecaAZN |
$66.6 0% | 54 |
 |
AbbVieABBV |
$171.56 0% | 52 |
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Michael McCaul |
Dec 18, 24 | Sell | $50K - $100K |
| Michael McCaul |
Nov 14, 24 | Buy | $15K - $50K |
| John James |
Sep 2, 24 | Buy | $1K - $15K |
Read more about Novo Nordisk (NVO) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, youtube subscribers, news mentions, customer reviews, lobbying cost, business outlook & linkedin employees.
What is the Market Cap of Novo Nordisk?
The Market Cap of Novo Nordisk is $353B.
What is Novo Nordisk's PE Ratio?
As of today, Novo Nordisk's PE (Price to Earnings) ratio is 26.86.
When does Novo Nordisk report earnings?
Novo Nordisk will report its next earnings on February 5 '25.
What is the current stock price of Novo Nordisk?
Currently, the price of one share of Novo Nordisk stock is $78.69.
How can I analyze the NVO stock price chart for investment decisions?
The NVO stock price chart above provides a comprehensive visual representation of Novo Nordisk's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Novo Nordisk shares. Our platform offers an up-to-date NVO stock price chart, along with technical data analysis and alternative data insights.
Does NVO offer dividends to its shareholders?
Yes, Novo Nordisk (NVO) offers dividends to its shareholders, with a dividend yield of 1.84%. This dividend yield represents Novo Nordisk's commitment to providing value to its shareholders through both potential capital appreciation and steady income. Investors considering Novo Nordisk in their portfolio should factor in this dividend policy alongside the company's growth prospects and market position.
What are some of the similar stocks of Novo Nordisk?
Some of the similar stocks of Novo Nordisk are Johnson & Johnson, Eli Lilly and Company, Pfizer, Astrazeneca, and AbbVie.
.